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Impaired insulin secretion and insulin resistance are the two 
main pathophysiological mechanisms that lead to type 2 diabe-
tes. It is well-known that type 2 diabetes is preceded by a long 
prediabetic state characterized by mild elevation of fasting and/
or postprandial glucose levels. However, previous studies on 
the relative contributions of insulin secretory defects and insu-
lin resistance in the development of impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT) have yielded con-
tradictory results [1-4]. Inconsistencies across the studies have 
been explained by differences in study populations, study de-
signs and methods to assess insulin resistance and insulin se-
cretion. 
  The nature of progressive β-cell failure occurring as normal 
glucose-tolerant (NGT) individuals progress to type 2 diabetes 
is incompletely understood. Moreover, the precise level of hy-
perglycemia at which β-cell function begins to decline has not 
yet been established. Research has shown that during the nat-
ural development of type 2 diabetes, fasting plasma insulin in-
creases and then decreases as insulin resistance develops, dis-
playing the typical inverted U-shaped curve that has been re-
ferred to as “Starling’s curve of the pancreas” [5]. Earlier stud-
ies reported that the plasma insulin response to glucose rises 
progressively until the fasting plasma glucose reaches 120 to 
140 mg/dL, and further increases in fasting glucose levels are 
associated with a progressive decline in insulin secretion [6]. 
  To date, several studies have examined insulin secretion as a 
function of glucose concentrations in various populations [7-
11]. Some studies have shown that individuals with IFG and/or 
IGT have a pronounced defect in early insulin secretion [7,12]. 
Other studies demonstrated that the decline in β-cell function 
occurs at an earlier stage that is considered normal according 
to current diagnostic criteria [8,10,11]. Only limited studies 
have assessed early insulin secretion based on dynamic tests in 
Koreans [13-16]. In the studies that do exist, the numbers of 
participants were small; no studies have yet assessed the chang-
es in insulin secretion in relation to the changes in fasting and 
postprandial glucose levels ranging from NGT to IGT and 
type 2 diabetes.
  In this issue, Rhee et al. [17] analyzed early-phase insulin 
secretion during oral glucose tolerance tests (OGTT) in rela-
tion to plasma glucose levels ranging from normal to the dia-
betic range of hyperglycemia in 873 Korean participants. The 
key finding of this report was that the decline of early-phase 
insulin secretion according to the increase of plasma glucose 
concentration begins early and progresses rapidly during the 
period generally designated as “normal.” According to their 
results, early-phase insulin secretion was reduced to <50% of 
the control group in participants with fasting glucose levels of 
100 mg/dL, postload 2-hour glucose of 145 mg/dL, and HbA1c 
of 5.8%. Therefore, the authors claim that the decline of early-
phase insulin secretion occurs most abruptly prior to the peri-
od we currently refer to as “prediabetes.” 
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  Then, as Rhee and colleagues suggested, should the criteria 
for “prediabetes” be changed? “Prediabetes” has been defined 
as the period during which the risk of developing type 2 dia-
betes are increased and thus preventive efforts are necessary. 
The diagnostic criteria for IFG and IGT are not defined on the 
basis of any pathophysiological abnormalities. Therefore, as 
discussed above, it is possible that the decline in β-cell function 
occurs at an earlier stage that is considered normal according 
to current diagnostic criteria. The American Diabetes Associa-
tion [18] recommended that IFG and/or IGT should not be 
viewed as clinical entities in their own right but rather as risk 
factors for diabetes as well as cardiovascular disease. In addi-
tion, defining a lower limit of a “prediabetes” category of glu-
cose levels is somewhat arbitrary, as the risk of diabetes with 
any measure of glycemia is a continuum that extends well into 
the normal ranges [18]. Therefore, to maximize the efficiency 
of preventive interventions, the cut point should balance the 
sensitivity and specificity. Prospective intervention studies are 
needed to determine whether “prediabetes” criteria should be 
changed. 
  The report of Rhee et al. [17] has several strengths. To our 
knowledge, this study included the largest number of Korean 
participants to date whose insulin secretory function was eval-
uated by OGTT. This relatively large sample size allowed inves-
tigators to assess the changes in early-phase insulin secretion in 
relation to fasting and postprandial glucose levels. They also 
carefully adjusted for the effects of insulin resistance on indi-
vidual changes in insulin secretion. Their study underscores 
the importance of insulin secretion defects in the pathogenesis 
of type 2 diabetes in Korean patients.
  However, as the authors pointed out, Rhee et al.’s study [17] 
also has several limitations that diminish our ability to draw 
definitive conclusions. Most importantly, as the participants 
were not randomly selected from the general population, the 
results are difficult to generalize to the entire Korean popula-
tion. In addition, the study’s cross-sectional design prohibited 
examining time-course or causal relationships. In addition, 
early-phase insulin secretion indices were measured based on 
OGTT instead of a gold-standard method such as a glucose-
clamp study or an intravenous glucose tolerance test. Another 
limitation would be that the participants included were “those 
with suspected abnormal glucose tolerance”; therefore, partic-
ipants categorized as NGT based on a one-time OGTT may 
not be completely normal, as the poor reproducibility of OGTT 
is a well-known problem. Previous studies have suggested that 
non-diabetic participants with a positive family history of dia-
betes have substantially reduced insulin secretion [19,20]. This 
study would have been more meaningful if a family history of 
type 2 diabetes had been considered in the analysis.
  Rhee et al.’s study also raises the question of whether Kore-
ans really have lower β-cell capacity than do Western popula-
tions. Previous studies have suggested that Koreans have lower 
insulin secretory capacity than Caucasians [13,21], and an ear-
ly-phase insulin secretory defect rather than insulin resistance 
may be a more important factor in the development of type 2 
diabetes in Koreans [14-16]. Unfortunately, we do not have the 
definitive answer yet, as there has been no study that directly 
compared insulin secretion of Koreans with that of other eth-
nic groups in the same study setting.
  The exact time-course changes of insulin secretion remain 
to be confirmed in longitudinal studies, although such studies 
are not easy to perform. While Rhee and colleagues’ study pro-
vides valuable information, more questions remain unanswered 
including the mechanism of decline in early-phase insulin se-
cretion. Further research is needed to address the pathogenic 
importance of early-phase insulin secretory dysfunction in the 
development of type 2 diabetes and to determine appropriate 
measures to prevent and treat these defects.
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